U.S. Circulating Tumor Cells Market Size & Outlook
Related Markets
U.S. circulating tumor cells market highlights
- The U.S. circulating tumor cells market generated a revenue of USD 5,587.5 million in 2025 and is expected to reach USD 14,754.0 million by 2033.
- The U.S. market is expected to grow at a CAGR of 13.2% from 2026 to 2033.
- In terms of segment, ctc detection & enrichment methods was the largest revenue generating technology in 2025.
- CTC Analysis is the most lucrative technology segment registering the fastest growth during the forecast period.
Circulating tumor cells market data book summary
| Market revenue in 2025 | USD 5,587.5 million |
| Market revenue in 2033 | USD 14,754.0 million |
| Growth rate | 13.2% (CAGR from 2026 to 2033) |
| Largest segment | Ctc detection & enrichment methods |
| Fastest growing segment | CTC Analysis |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis |
| Key market players worldwide | Qiagen NV, Bio-Techne Corp, Praxis Precision Medicines Inc Ordinary Shares, Aviva PLC, Biocept Inc, Neurocrine Biosciences Inc, Greiner Bio-One, Miltenyi Biotec, Icon PLC, Ecolab Inc, Arcus Biosciences Inc, Epic Corp, Screen Holdings Co Ltd, Menarini Group, Vtex Ordinary Shares - Class A, Sysmex Corp, STEMCELL Technologies |
Other key industry trends
- In terms of revenue, U.S. accounted for 39.8% of the global circulating tumor cells market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In North America, U.S. circulating tumor cells market is projected to lead the regional market in terms of revenue in 2033.
- U.S. is the fastest growing regional market in North America and is projected to reach USD 14,754.0 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Circulating Tumor Cells Market Scope
Circulating Tumor Cells Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Vtex Ordinary Shares - Class A | View profile | 1277 | 125 Kingsway, Aviation House, London, United Kingdom, WC2B 6NH | https://www.vtex.com |
| Arcus Biosciences Inc | View profile | 577 | 3928 Point Eden Way, Hayward, CA, United States, 94545 | https://www.arcusbio.com |
| Neurocrine Biosciences Inc | View profile | 1448 | 12780 El Camino Real, San Diego, CA, United States, 92130 | https://www.neurocrine.com |
| Praxis Precision Medicines Inc Ordinary Shares | View profile | 82 | 99 High Street, 30th Floor, Boston, MA, United States, 02110 | https://www.praxismedicines.com |
| STEMCELL Technologies | View profile | 501-1000 | Vancouver, British Columbia, Canada, North America | https://www.stemcell.com |
| Menarini Group | View profile | 1001-5000 | Firenze, Toscana, Italy, Europe | http://www.menarini.com |
| Greiner Bio-One | View profile | 1001-5000 | Monroe, North Carolina, United States, North America | https://www.gbo.com/en_US/ |
| Ecolab Inc | View profile | 48000 | 1 Ecolab Place, Saint Paul, MN, United States, 55102 | https://www.ecolab.com |
| Aviva PLC | View profile | 23247 | St Helen's, 1 Undershaft, London, United Kingdom, EC3P 3DQ | https://www.aviva.com |
| Screen Holdings Co Ltd | View profile | 6589 | Tenjinkita-machi 1-1, Teranouchi-agaru, 4-chome, Horikawa-dori, Kamigyo-ku, Kyoto, Japan, 602-8585 | https://www.screen.co.jp |
| Miltenyi Biotec | View profile | 1001-5000 | Bergisch Gladbach, Nordrhein-Westfalen, Germany, Europe | http://www.miltenyibiotec.com |
| Icon PLC | View profile | 41150 | South County Business Park, Leopardstown, Dublin, Ireland, D18 X5R3 | https://www.iconplc.com |
| Bio-Techne Corp | View profile | 3050 | 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 | https://www.bio-techne.com |
| Sysmex Corp | View profile | 10448 | 1-5-1 Wakinohara-Kaigandori, Chuo-ku, Hyogo Prefecture, Kobe, Japan, 6510073 | http://www.sysmex.co.jp |
| Biocept Inc | View profile | 50 | 9955 Mesa Rim Road, San Diego, CA, United States, 92121 | https://www.biocept.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Epic Corp | View profile | 2 | PO Box 11147, Newport Beach, CA, United States, 92658 |
U.S. circulating tumor cells market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to circulating tumor cells market will help companies and investors design strategic landscapes.
Ctc detection & enrichment methods was the largest segment with a revenue share of 55.71% in 2025. Horizon Databook has segmented the U.S. circulating tumor cells market based on ctc detection & enrichment methods, ctc direct detection methods, ctc analysis covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. branded generics market is anticipated to witness moderate growth over the forecast period, owing to increase in number of ANDA approvals and first-to-file benefits, such as Paragraph IV (PIV) certification. In addition, 107 first generic products were approved, which may contribute to market growth due to increased profitability through 180 days of exclusivity period.
Between 2017 and August 2019, key players such as Teva Pharmaceutical Industries Ltd. filed 160 PIVs followed by Mylan N.V. with 81 PIVs. Moreover, advances by pharmaceutical companies to develop complex generics and involvement in Active Pharmaceutical Ingredients (API) business may contribute to market growth.
The buyers in the U.S. are leveraging the strong competition between manufacturers and excess capacity in manufacturing and R&D. Purchasing organizations, such as Red Oak Sourcing, Econdisc Contracting Solutions, and Walgreens Boots Alliance with AmerisourceBergen, representing 90% of the U.S. market are poised to lower prices of suppliers and draw significant discounts on all inputs, including new branded generics.
Reasons to subscribe to U.S. circulating tumor cells market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. circulating tumor cells market databook
-
Our clientele includes a mix of circulating tumor cells market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. circulating tumor cells market , including forecasts for subscribers. This country databook contains high-level insights into U.S. circulating tumor cells market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. circulating tumor cells market size, by technology, 2021-2033 (US$M)
U.S. Circulating Tumor Cells Market Outlook Share, 2025 & 2033 (US$M)
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
